The Royalty Transparency Act amends the federal financial disclosure regime to force certain executive-branch officials, special Government employees, and members of enumerated public-health and science advisory committees to report the original source and amount or value of royalties tied to inventions developed during government employment. The bill overrides existing confidentiality provisions in the Stevenson‑Wydler Act and certain patent statutes for these royalty disclosures, requires agencies to publish information online, and directs the GAO to identify advisory committees covered by the rule.
The bill also tightens oversight: it mandates immediate notification to congressional oversight committees when ethics waivers or exemptions are granted, requires agencies and the FAR/OMB to incorporate royalty payments into conflict-of-interest reviews for contractors and grantees, and obliges agencies to provide unredacted financial disclosures to Members of Congress within 30 days (with limited PII redactions). Those rules aim to surface financial ties that could affect policymaking, procurement, and advisory recommendations.
At a Glance
What It Does
The bill amends multiple sections of title 5 and title 18 U.S. Code to require reporting of royalty source and amount for covered executive-branch employees and named advisory committee members, directs agencies to post and report that information, and orders the FAR Council and OMB to include royalty history in COI reviews for contractors and grantees.
Who It Affects
Covered groups include specified vaccine, biosecurity, and science advisory committees (and successors), executive branch officers and employees (including special Government employees), agency ethics offices, and prospective federal contractors and grantees subject to COI screening.
Why It Matters
It eliminates statutory confidentiality that has shielded royalty amounts tied to government inventions, creating a new transparency regime that could change how outside experts engage with agencies, how agencies assess contractor independence, and how commercial technology transfer is managed.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites parts of the federal ethics and disclosure code to pull royalties into plain sight. It adds a new category of filers—members of a set of named advisory committees and any successor bodies that the GAO finds have made implementable public‑health recommendations—and requires those filers to list the original source and amount or value of any royalties they, their spouse, or dependent children received from inventions developed in the course of their government employment.
Where previous law allowed some royalty information to remain confidential under technology-transfer and patent statutes, this bill requires agencies to collect and, in many cases, publish that information.
On process, the legislation makes several procedural changes. The GAO must publish a list, initially within 180 days and then annually, of advisory committees that meet the statute’s criteria.
Agencies must publish financial disclosure reports on their websites (notwithstanding prior confidentiality rules) and furnish unredacted copies to Members of Congress within 30 days of request, omitting only certain PII fields. For confidential filers, agencies must produce annual aggregated reports to oversight committees describing filing counts, subcomponents, reasons for confidentiality, and counts of special Government employees required to file confidentially; agencies must also annually publish a list of covered individuals and the royalty amounts those individuals reported.The bill inserts royalty history into federal acquisition policymaking: the FAR Council and OMB must promulgate or update regulations so agency conflict-of-interest reviews for prospective contractors and grantees consider royalties paid to them in the prior calendar year.
Agencies must report annually to oversight committees (and intelligence oversight where applicable) on identified potential COI cases tied to royalty payments and mitigation steps taken. Finally, the bill requires immediate reporting to specified congressional committees whenever ethics waivers or certain statutory exemptions are granted, and includes a five-year sunset on the statutory expansion that lists specific advisory committees (with successor‑committee language surviving).
The Five Things You Need to Know
The bill adds subsection (f)(13) to 5 U.S.C. §13103 to make members of 11 named advisory committees—and successor committees the GAO identifies—subject to financial disclosure rules for royalties.
GAO must publish, within 180 days and annually, a list of advisory committees that made public-health recommendations and had any recommendation fully or partially implemented in the prior 10 years.
Agencies must collect and publish the original source and amount/value of royalties tied to inventions developed during government employment, explicitly overriding prior confidentiality under the Stevenson‑Wydler Technology Innovation Act and 35 U.S.C. provisions for those disclosures.
Members of Congress may obtain unredacted copies of executive-branch financial disclosure reports within 30 days of request, subject only to redaction of limited PII (SSNs, DOBs, home/rental addresses, phone/email, account numbers, signatures, dependent children’s PII).
The FAR Council and OMB must update acquisition regulations so COI reviews for prospective contractors or grantees include an examination of royalties paid to those entities in the previous calendar year, and agencies must annually report identified royalty-related COIs and mitigation steps to oversight committees.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the bill the short title "Royalty Transparency Act." Mechanically important but purely formal; it doesn’t change substance or create obligations beyond naming the act.
Expand who must file and GAO determinations
This amendment inserts a new paragraph into the definition of filers to capture members of eleven enumerated advisory committees (vaccine, biosecurity, science, defense-related boards) and any successor committee that GAO later finds meets the statutory test. Practically, that pulls many outside experts—often appointed as special Government employees—under the financial disclosure rules that require royalty reporting. The inclusion is time-limited for the enumerated list by a five‑year sunset on the explicit naming, but successor‑committee language remains.
Immediate congressional notice when ethics waivers or exemptions issued
The bill tightens waiver transparency: supervising ethics offices must now notify four named congressional committees when they determine a waiver is appropriate, and Title 18 is amended to require immediate reporting to those same committees when certain exemptions under §208 are granted, including a detailed justification. That creates an expedited congressional visibility path whenever an employee’s conflict is waived.
Mandatory royalty detail, public posting, and Member access
These coordinated edits require disclosure of the original source and amount/value of royalties traced to inventions developed during government employment and instruct agencies to post financial reports on their websites. Agencies must also provide unredacted copies to Members of Congress within 30 days (with enumerated PII redactions) and produce annual internal reports about confidential filers—how many filed, which subcomponents, and why confidentiality was used. For covered confidential filers, agencies must publish a list of names and the royalty amounts reported once a year, substantially narrowing prior confidentiality protections for technology-transfer proceeds.
Streamlined process for congressional review
The bill changes the mechanics for inspecting reports: it directs agencies to make reports available online and obliges agencies to furnish unredacted copies to Members of Congress within 30 days. Operationally this requires agencies to adapt IT platforms, establish secure transfer channels for Members, and create redaction workflows limited to specific PII fields.
Royalty consideration in federal acquisition COI reviews
The FAR Council and OMB must enact or update regulations so COI reviews of prospective contractors and grantees explicitly include an examination of royalties paid to them in the preceding calendar year. Agencies must then report annually to oversight and intelligence committees (where applicable) on the number of potential royalty-related COI cases and mitigation steps, effectively making past royalty receipts a factor in award decisions and post‑award monitoring.
This bill is one of many.
Codify tracks hundreds of bills on Government across all five countries.
Explore Government in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Congressional oversight committees — gain faster, broader access to royalty and disclosure data (including unredacted reports within 30 days) to investigate conflicts, waivers, and implementation of agency ethics commitments.
- Public-health stakeholders and the general public — obtain transparency about financial ties between advisory committee members and commercial beneficiaries of government‑developed inventions, which can inform trust in recommendations on vaccines and biosecurity.
- Competing companies and potential government contractors — benefit from COI reviews that consider royalties, improving fairness in procurement decisions where incumbent licensees or related parties hold royalty streams that could bias outcomes.
Who Bears the Cost
- Federal agencies and ethics offices — will absorb administrative, IT, and legal costs to collect royalty data, publish reports, process redactions, and respond to Member requests; intelligence components may face particularly onerous coordination burdens.
- Advisory committee members and outside experts (often academics or small‑company founders) — bear privacy and reputational costs when royalties tied to commercialization are posted publicly; anticipated disclosure may deter participation as special Government employees.
- Technology transfer offices, licensees, and startups — face commercial sensitivity and potential competitive harms from public disclosure of royalty amounts, and may see negotiation leverage shifted if royalty streams are used as COI triggers in procurement and grant decisions.
Key Issues
The Core Tension
The central tension is between making payments that could influence public-policy or procurement decisions fully visible to deter conflicts, and protecting privacy, commercial confidentiality, and the government’s ability to recruit outside expertise; increasing transparency reduces informational asymmetries but risks chilling expert participation and exposing negotiated commercial terms or classified work.
The bill attempts to thread two conflicting policy aims—greater transparency about potential financial conflicts and preserving confidentiality around government technology commercialization—but raises several implementation questions. First, it asserts disclosure "notwithstanding" Stevenson‑Wydler and certain patent‑statute confidentiality provisions, yet those statutory frameworks and related license agreements can contain trade-secret or proprietary‑information claims; agencies will need new legal templates to collect and publish royalty amounts without triggering contract or IP disputes.
Second, the statute requires agencies to post names and dollar values for covered confidential filers, a step that heightens privacy and commercial sensitivity and may prompt legal challenges over disclosure of commercially negotiated terms or classified work.
Operationally, the bill places significant burdens on agency IT systems, ethics offices, and the FAR Council/OMB to craft new regulations and reporting pipelines on a short clock (GAO list in 180 days; annual reporting deadlines). The interplay with intelligence community classifications is only partially addressed: the bill requires intelligence agencies to report to their oversight committees, but the public‑posting and Member‑access rules could clash with security determinations.
Finally, the bill lacks enforcement mechanisms and valuation standards—there’s no guidance on how to value royalty streams, whether contingent/earned vs. accrued royalties must be reported, or how family member royalties are to be traced and verified, which will create interpretive disputes between filers and ethics officials.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.